Summary Somatostatin is a widely distributed inhibitory peptide with growth-inhibitory effects in several human tumours, including breast cancer, raising the possibility that it may have therapeutic potential. The effects of somatostatin are mediated via a family of cell-surface receptors that differ in their tissue distribution, pharmacological properties and intracellular response mediators, suggesting that they mediate different functions of the peptide. We have analysed the expression of somatostatin receptor subtype (SSTR1-5) mRNA in normal and malignant breast tissue. Receptor expression was analysed by reverse transcription-polymerase chain reaction (RT-PCR) using receptor subtype-specific primers and by in situ hybridization (ISH) with riboprobes synthesized by in vitro transcription of cloned PCR products. A total of 51 breast carcinomas, 36 samples of matched normal tissue, two axillary node metastases and eight normal/benign breast tissue samples were analysed. SSTR2 expression was ubiquitous in both normal and malignant breast tissue. Expression of SSTR5 was detected in approximately one-third of tumour and normal tissue, but fewer than 13% of all tissues expressed SSTR1, 3 and 4. These data suggest that SSTR2 gene expression is ubiquitous in breast cancer. Although this is unlikely to have diagnostic or prognostic significance, SSTR2-specific somatostatin analogues may have therapeutic potential in breast cancer.
Somatostatin is a widely distributed, multifunctional peptide hormone that is unique in that its physiological actions are almost universally inhibitory (Reichlin, 1983a,b) . Negative growth-regulatory properties of somatostatin have been shown in a number of human tumours, including breast cancer (Schally, 1988) , suggesting that it may have therapeutic potential in oncology. The clinical use of native somatostatin, however, is limited by its short half-life in the circulation and the broad spectrum of its physiological actions. These problems have been circumvented by the development of synthetic structural analogues of somatostatin with enhanced selectivity and greater stability (Schally, 1988; Schally et al, 1986) . Growth inhibition by somatostatin and its analogues occurs both indirectly, through the modulation of secretion of trophic peptide hormones and growth factors, and directly via interaction with tumour cells. There is also experimental evidence that somatostatin inhibits angiogenesis, which is essential for tumour development and growth (Woltering et al, 1990) . At the cellular level, the diverse physiological effects of somatostatin are mediated via interaction with a family of specific cell-surface receptors. Five distinct somatostatin receptor subtypes have been identified, cloned, sequenced and partially characterized (Yamada et al, 1992a (Yamada et al, ,b, 1993 O'Carroll et al, 1994; Rohrer et al, 1993) .
Although these receptors have a similar affinity for endogenous somatostatin, their affinity for its structural analogues differs, complicating the interpretation of receptor studies that have been carried out using these analogues (Hoyer et al, 1994) . However, it appears that the five receptor subtypes have a distinct, but overlapping, tissue distribution, unique pharmacological properties and are coupled to a number of intracellular signalling pathways, suggesting that they mediate different functions of the native peptide (Hofland et al, 1995) . There is evidence that the direct growth-inhibitory effects of somatostatin are mediated, at least in part, by the activation of intracellular phosphatases (Liebow et al, 1989) , and receptor subtypes 1 and 2 have been shown to be coupled to this intracellular pathway (Buscail et al, 1994 (Buscail et al, -1995 . However, growth inhibition has also been shown to be mediated by receptor subtype 5 independently of intracellular phosphatases (Buscail et al, 1995) , suggesting that other pathways are also involved in direct growth inhibition.
Somatostatin receptors have been demonstrated in up to 75% of human primary breast cancers by biochemical cross-linking techniques (Prevost et al, 1993) , in vitro autoradiography (Papotti et al, 1989; Reubi and Torhorst, 1989; Reubi et al, 1990; van Eijck et al, 1994) and in vivo scintigraphy (van Eijck et al, 1994; Krenning et al, 1993) using various synthetic analogues of somatostatin. No study, however, has addressed the expression of different receptor subtypes in breast tissue, knowledge of which is critical, if the growth-inhibitory effects of somatostatin in breast cancer are to be therapeutically exploited. In this study, we have analysed the somatostatin receptor subtype expression in benign and malignant breast tissue by reverse transcription-polymerase chain reaction and in situ hybridization.
MATERIALS AND METHODS Tissue collection
Fresh tissue samples were obtained from patients undergoing surgery for breast disease. Tissues were dissected out, snap frozen in liquid nitrogen for transport and subsequently stored at -80°C until analysed (0-12 months). The nature of all specimens was confirmed histologically by a trained pathologist.
RNA extraction
Total cellular RNA was isolated from frozen tissue by phenol-guanidinium extraction (Chomczynski and Sacchi, 1987) using a commercially available kit (RNazol B, Biogenesis).
DNAase treatment RNA Each of the five SSTR subtypes is encoded by an intronless gene. As such, even minute amounts of genomic DNA contaminating cDNA samples can be amplified by the sensitive technique of PCR, producing a false-positive result. All RNA samples were, therefore, treated with RNAase-free DNAase before reverse transcription. Total RNA was incubated for I h at 37°C in a 50-,ul reaction containing 40 mM Tris-HCl, pH 7.9, 10 mm sodium chloride, 6 mm magnesium chloride, 10 mm calcium chloride, 25 units RNAase-free RQ1 DNAase and 40 units RNAase inhibitor (all reagents from Promega). Following digestion of DNA, DNAasefree RNA was extracted with phenol-chloroform, precipitated with 100% ethanol and 2.5 M sodium acetate (pH 4) at -20°C overnight and taken up in 50 jil of DEPC-treated, RNAase-free water. The final concentration of DNA-free RNA was determined by absorbance at 260X (1 OD = 40 jig ml-') and solutions were stored at -80°C.
Reverse transcription A sample of 5 jg of total DNA-free RNA was subjected to reverse transcription using the Stratagene (RT-PCR kit). The completed reaction products were stored at -20°C.
Polymerase chain reaction
Before analysis of SSTR expression, the presence of equal amounts of amplifiable cDNA was confirmed for each reverse transcription reaction by PCR using primers for the constitutively expressed message P-actin (primers and conditions obtained from Stratagene). All oligonucleotide primers for SSTR PCR reactions were purchased from Cruachem Ltd., Glasgow, UK, and were supplied and used as aqueous solutions without high-performance liquid chromatography (HPLC) purification. Primer sequences for each somatostatin receptor subtype were determined from the (Yamada et al, 1992a (Yamada et al, , 1993 using the 'Primer' software program (Version 0.5, Whitehead Institute for Biomedical Research, Cambridge, MA, USA). The upstream primer (PU) and downstream primer (PD) sequences for SSTR 1-5 are shown in Table 1 .
Amplification of SSTR cDNA transcripts was performed in a final volume of 25 jl, using as a substrate 5% (2.5 jl) of the cDNA synthesized by reverse transcription of 5 jig of total RNA as described above. All reagents were obtained from Promega. Reactions were carried out in 1 x PCR buffer (50 mm potassium chloride, 10 mM Tris-HCl, pH 9.0 at 25°C, 0.1% Triton X-100, 1.5 mm magnesium chloride in a final concentration of 800 jiM dNTPs (200 gM-each of dATP, dCTP, dGTP and dTTP), 0.5 U Taq polymerase and 1 jiM each primer. The optimized PCR conditions were identical for each pair of primers except for the final concentration of dimethylsulphoxide (DMSO) which was 0% for SSTR2, 2% for SSTR1, 3 and 5, and 5% for SSTR4. Reactions were made up to 25 jl with RNAase-free water, overlaid with 25 jl of mineral oil to prevent evaporation and subjected to amplification in a Perkin Elmer DNA thermal cycler model 480. Amplification was carried out for 35 cycles at 94°C for 30 s (denaturation), 60°C for 30 s (annealing) and 72°C for 30 s (extension).
Aliquots (10 jl) of each completed PCR reaction were resolved on 2% agarose gels containing 0.5 jig ml-' ethidium bromide together with DNA markers of known molecular weight visualized under ultraviolet light and photographed.
Control experiments
For SSTR PCR, each sample was run with a negative control using as a substrate DNAase-treated RNA, which was treated in parallel with the test samples, but without addition of the reverse transcriptase enzyme. For each batch of PCR, a genomic DNA sample was included as a positive control and a further tube without any nucleic acid substrate was used as a negative control to exclude contamination of reagents. For each cDNA, a minimum of two independent PCRs was performed for each SSTR subtype.
Verification of PCR products Amplified PCR products were verified by (1) sequencing of cloned PCR products; (2) Southern blotting and hybridization with receptor subtype-specific probes.
Sequencing PCR products were cloned into pGem-T (Promega), transformed into competent E. coli cells and characterized by dideoxy sequencing using the T7 kit obtained from Pharmacia Biotech. For each receptor subtype, the anticipated PCR product sequence was obtained.
Southern blotting PCR products were transferred to nylon membranes by capillary blotting and hybridization analysis was performed with cDNA probes labelled to high specific activity with [ax2P]dCTP by random priming ('Rediprime', Amersham, UK).
In situ hybridization RT-PCR was chosen because it is an exquisitely sensitive technique that will amplify small quantities of messenger RNA, and in many cases only small amounts of tissue were available for analysis. ISH is less sensitive, but allows nucleic acids to be visualized in their cellular environment and was used to localize mRNA expression in the tissues studied. The most striking observation from this study is that SSTR2 is ubiquitously expressed in breast cancer. Only one tumour out of 51 was SSTR2 negative on RT-PCR, and expression was subsequently detected in this tumour by ISH. This finding is in agreement with previous studies, which have shown that SSTR2 is commonly expressed in human tumours (Eden and Taylor, 1993; Reubi et al, 1994) . SSTR2 expression was detected less often in normal breast tissue by RT-PCR (44% matched normal, 62.5% benign/normal), but ISH revealed that histologically normal breast epithelial cells also universally express SSTR2. The apparent lower sensitivity of RT-PCR compared with ISH probably results from the relative paucity of epithelial cells in normal breast tissue compared with tumour. Virtually all the women from whom matched normal tissue was obtained in this study were peri-or post-menopausal (mean age, 60 years; range 42-79 years), an age at which the breast consists primarily of fat with little epithelial tissue identifiable histologically. In fact, matched normal tissue was only available for analysis in 36 of 51 cancer patients because tissue samples from the remaining 15 patients were found to contain no normal epithelial tissue. The benign/normal tissues were obtained from a younger age group (mean age, 45 years; range 26-60 years) undergoing surgery for benign breast disease. In this younger age group, epithelial tissue may have been more abundant, and 62.5% of these tissues were SSTR2 positive. Tissue sections used for ISH were selected for their high content of both benign and malignant epithelium, and the sensitivity of PCR could similarly be improved by microdissection of tissue samples before analysis. A similar pattern of expression was seen for SSTR5, which was the next most commonly expressed mRNA. Approximately one-third of tumours and benign/normal breast tissue expressed this gene, as determined by RT-PCR, compared with only 5.5% of matched normal tissue, suggesting that expression of SSTR5 may be more tumour-specific than SSTR2. However, ISH again demonstrated that when SSTR5 was expressed by tumours, it was also expressed by normal tissue within the same tissue section, suggesting that RT-PCR has underestimated the expression of SSTR5 mRNA in matched normal tissue. The results of ISH indicate that tumours arising in breast tissue expressing SSTR5 mRNA retain this expression, and those arising in SSTR5-negative breast tissue remain SSTR5-negative. SSTR5 is the most recently described of the five SSTRs and, as such, little work has previously been reported on its expression for comparison with these results.
There was good correlation overall between the results for ISH and those for RT-PCR for both SSTR2 and SSTR5. For ISH, all positive cases demonstrated cytoplasmic staining in both normal and malignant epithelial cells, although in some cases staining was heterogeneous. This is most likely to represent artefact, but would be consistent with the results of some affinity binding studies, which have demonstrated heterogeneous distribution of somatostatin receptors (Reubi et al, 1990; Papotti et al, 1989 ).
The remaining three receptor subtypes (SSTR1, SSTR3 and SSTR4) were expressed infrequently in both tumour and normal tissue, and ISH was not carried out for these receptors. Previous studies have shown that these receptors are less commonly expressed than SSTR2 and are seen mainly in endocrine and gastrointestinal tumours (Eden and Taylor, 1993; Reubi et al, 1994) .
The results of this study must be interpreted with caution because the detection of gene expression, as determined by the presence of mRNA, does not necessarily imply the expression of a functional cell-surface receptor. However, it has been shown that the detection of SSTR mRNA by ISH correlates well with cell surface receptor detection by in vitro binding with native somatostatin and its analogues .
The data presented in this study are particularly relevant to the application of currently available somatostatin analogues to the treatment of breast cancer, a disease which causes 16 000 deaths per year in the UK. Both direct and indirect growth-inhibitory effects of somatostatin and its analogues have been demonstrated in breast cancer on cell lines in vitro (Setyono-Han et al, 1987; Scambia et al, 1988) and tumour xenografts in vivo (Weber et al, 1989; Noguchi et al, 1993) . Indirect growth inhibition is likely to be secondary to a decrease in systemic and local levels of peptides known to be trophic for breast cancer cells, such as growth hormone (Rose et al, 1983 ) and its mediator insulin growth factor 1 (IGF-1) (Pollack et al, 1989) , insulin (Furlanetto and DiCarlo, 1984) and epidermal growth factor (EGF) (Ghirlanda et al, 1983) . In this respect, the effects of somatostatin and its analogues have been shown to be synergistic with LHRH agonists (Szende et al, 1989) and tamoxifen (Huynh and Pollack, 1994; Weckbecker et al, 1994) . Direct growth-inhibitory effects are mediated via specific high-affinity tumour cell surface receptors, but it is unclear at present which of the five receptor subtypes so far identified are responsible for this effect and which intracellular pathway is involved.
The five SSTRs are G-protein-coupled receptors (GPRs) that exhibit 40-60% overall sequence homology (Yamada et al, 1993) . They have a similar affinity for endogenous somatostatin and are all coupled via pertussis toxin-sensitive G-proteins to adenylate cyclase (Patel et al, 1994) . However, there are important differences between the receptor subtypes, which suggest that they may mediate different functions of the native peptide. Each receptor subtype has a distinct tissue distribution, different ligand specificities and is linked to different intracellular coupling systems in addition to adenyl cyclase (reviewed in Hofland et al, 1995) . Structurally, the greatest homology is between SSTR2, SSTR3 and SSTR5 on the one hand and SSTR1 and SSTR4 on the other, and these structural homologies translate into similar pharmacological profiles (Serrano et al, 1993) . The three analogues of somatostatin that are currently in clinical use, octreotide, RC-160 and BIM-23014 (lanreotide), bind with high affinity to SSTR2, SSTR5 and with moderate affinity to SSTR3, but have very low affinity for SSTR1 and SSTR4 (Hoyer et al, 1994) .
There is experimental evidence that the direct growth-inhibitory effects of somatostatin are mediated via receptor subtypes 1, 2 and 5. Buscail et al (1995) demonstrated that of the five SSTR subtypes, only SSTR2 and SSTR5 produced growth inhibition in CHO cells, but by different mechanisms, SSTR2 acting via the stimulation of tyrosine phosphatases and SSTR5 via the inhibition of intracellular calcium mobilization. SSTR1 has also been shown to mediate growth inhibition through tyrosine phosphatases, but in different cell lines (COS-7 and NIH 3T3 cells) (Buscail et al, 1994 ).
In summary, there is a considerable body of experimental evidence to suggest that somatostatin analogues have growthinhibitory effects in cancer. Indirect growth inhibition is likely to be non-specific, but evidence suggests that direct growth inhibition will be most effective in those tumours that express somatostatin receptor subtypes 1, 2 or 5. In this study, we have demonstrated that two of the SSTRs that mediate direct growth inhibition are expressed in breast cancer. SSTR2 is expressed in all tumours and SSTR5 is expressed in approximately one-third of tumours. Structural analogues of somatostatin with high affinity for both of these receptor subtypes are already available and in safe clinical use, and these analogues may therefore have a significant role in the management of breast cancer.
